HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Neutral rating on Ventyx Biosciences (NASDAQ:VTYX) and maintained a $6 price target.
June 13, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Neutral rating on Ventyx Biosciences and maintained a $6 price target.
The reiteration of a Neutral rating and maintenance of the $6 price target suggests that the analyst does not foresee significant short-term changes in the stock's performance. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100